Background: The biological function and prognostic significance of endothelial cell specific molecule 1 (ESM1) in various cancers have been validated. This study aimed to explore the expression and clinical diagnosis values in patients with stomach adenocarcinoma (STAD) and esophageal carcinoma (ESCA).
Methods: Online database Gene Expression Omnibus was used to screen for abnormally expressed genes in STAD and ESCA. Besides, 36 STAD and 36 ESCA patients were enrolled, and their corresponding control groups were also 36 people each. Reverse transcription-quantitative polymerase chain reaction and Western blot were performed to analyze the expression of ESM1. Overall survival (OS) curve and receiver operating characteristics curve (ROC) analysis were used to assess the prognosis, and the sensitivity and specificity of ESM1 for the diagnosis of STAD and ESCA, respectively. Additionally, the effects of ESM1 on cell viability, migration, and invasion were analyzed by cell counting kit-8, transwell migration and invasion assays.
Results: The results showed that the poor OS of STAD and ESCA patients was correlated with high ESM1. Besides, ESM1 was increased in ESCA and STAD in in vivo and in vitro studies. ESM1 has a high accuracy [area under the curve (AUC) > 0.79] at stage I and IV of STAD and ESCA. Knockdown of ESM1 suppressed the cell viability, migration, and invasion and increased the apoptosis rate of AGS and TE1 cells.
Conclusion: Our study suggested that ESM1 might be used as a new indicator for the diagnosis and prognosis of early and advanced stage digestive tract cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193464 | PMC |
| http://dx.doi.org/10.2147/IJGM.S456973 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of ROMO1 Expression Levels and Its Oncogenic Role in Gastrointestinal Tract Cancers.
Curr Issues Mol Biol
December 2024
Department of Medical Biochemistry, Trabzon Kanuni Health Practice and Research Hospital, Trabzon Faculty of Medicine, University of Health Sciences, Trabzon 61250, Turkey.
Gastrointestinal tract cancers account for approximately one-third of cancer-related deaths. Early diagnosis and effective treatment are the most important ways to prevent cancer-related morbidity and mortality. ROMO1 has been shown to play an important role in many types of cancer.
View Article and Find Full Text PDFContinuous prediction for tumor mutation burden based on transcriptional data in gastrointestinal cancers.
BMC Med Inform Decis Mak
December 2024
Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, China.
Background: Tumor mutation burden (TMB) has been considered a biomarker for utilization of immune checkpoint inhibitors(ICIs), but whole exome sequencing(WES) and cancer gene panel(CGP) based on next generation sequencing for TMB detection are costly. Here, we use transcriptome data of TCGA to construct a model for TMB prediction in gastrointestinal tumors.
Methods: Transcriptome data, somatic mutation data and clinical data of four gastrointestinal tumors from TCGA, including esophageal cancer (ESCA), stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ).
Shared and specific competing endogenous RNAs network mining in four digestive system tumors.
Comput Struct Biotechnol J
December 2024
Key Laboratory of Computer-Aided Drug Design of Dongguan City, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan 523710, China.
Background: Digestive system malignancies, including esophageal carcinoma (ESCA), stomach adenocarcinoma (STAD), liver hepatocellular carcinoma (LIHC), and colon adenocarcinoma (COAD), pose significant global health challenges. Identifying shared and distinct regulatory mechanisms across these cancers can lead to improved therapies. This study aims to construct and compare competing endogenous RNA (ceRNA) networks across ESCA, STAD, LIHC, and COAD to identify RNA biomarkers that could serve as precision therapeutic targets to enhance clinical outcomes and advance personalized cancer care.
View Article and Find Full Text PDFIdentification of common core genes and pathways in childhood sepsis and cancer by bioinformatics analysis.
Discov Oncol
December 2024
Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Introduction: Sepsis and cancer are both leading causes of death worldwide, and they share several pathophysiological characteristics. Some studies have suggested a possible association between sepsis and cancer; however, few have investigated the core genes involved in both diseases.
Methods: Core genes common to both sepsis and cancer were identified using pediatric sepsis datasets (GEO: GSE26378, GSE4607, GSE8121 and GSE13904) and cancer databases (TCGA: BRCA, COADREAD, ESCA, KIRC, LIHC, LUAD, STAD).
Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.
Heliyon
November 2024
Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, 710061, China.
Article Synopsis
- CD73 is an important molecule involved in immune regulation and its role in the tumor microenvironment was investigated using multiple cancer databases, revealing elevated levels in several cancer types like esophageal carcinoma and glioblastoma.
- The study found that high CD73 expression was often linked to poor overall survival in various cancers such as breast and lung cancers, although in some cases (like kidney and uterine cancers), high expression was associated with better outcomes.
- Additionally, tumors with high CD73 expression showed increased immune scores and positive correlations with immune cell infiltration, indicating a complex relationship between CD73 and the immune response in tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!